Administration of 3-Deazaneplanocin A (DZNep) has been shown to effectively inhibit the specific binding of EZH2 to the proximal promoter of PTEN, thereby reducing PTEN mRNA transcription levels and ameliorating CKD-associated pathological damage [57]. The gene discussed is EZH2; the disease is chronic kidney disease.